BRIEF-Bristol-Myers Says After Breakfree-2 Study Data Cutoff, One haRMS Patient Experienced A Fatal Event Of Septic Pneumonia

3

Oct 23 (Reuters) – Bristol-Myers Squibb Company: * BRISTOL MYERS SQUIBB PRESENTS RESULTS FROM PHASE 1 BREAKFREE-2 STUDY OF ZOLACABTAGENE AUTOLEUCEL (BMS-986353) IN PATIENTS WITH HIGHLY ACTIVE

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)